RA. Hypoxia-induced mitogenic factor/FIZZ1 induces intracellular calcium release through the PLC-IP3 pathway. Am J Physiol Lung Cell Mol Physiol 297: L263-L270, 2009. First published May 8, 2009 doi:10.1152/ajplung.90416.2008.-Hypoxia-induced mitogenic factor (HIMF), also known as "found in inflammatory zone 1" (FIZZ1) or resistin-like molecule-␣ (RELM␣), is a profound vasoconstrictor of the pulmonary circulation and a strong mitogenic factor in pulmonary vascular smooth muscle. To further understand the mechanism of these contractile and mitogenic responses, we examined the effect of HIMF on intracellular Ca 2ϩ in human pulmonary artery smooth muscle cells (SMC). Ca 2ϩ imaging in fluo 4-loaded human pulmonary artery SMC revealed that recombinant murine HIMF increased intracellular Ca 2ϩ concentration ([Ca 2ϩ ]i) in a sustained and oscillatory manner. This increase occurred independent of extracellular Ca 2ϩ influx. Pretreatment of human pulmonary artery SMC with U-73122, a specific inhibitor of phosphatidylinositolphospholipase C (PLC) completely prevented the HIMF-induced Ca 2ϩ signal. The [Ca 2ϩ ]i increase was also abolished by pretreatment with 2-aminoethoxydiphenyl borate (2-APB), an inositol 1,4,5-trisphosphate (IP 3) receptor antagonist. Ryanodine pretreatment did not affect initiation of [Ca 2ϩ ]i activation or internal release but reduced [Ca 2ϩ ]i at the plateau phase. Pretreatment with the G␣i-specific inhibitor pertussis toxin and the G␣ s-specific inhibitor NF-449 did not block the Ca 2ϩ signal. Knockdown of G␣q/11 expression did not prevent Ca 2ϩ release, but the pattern of Ca 2ϩ release changed from the sustained oscillatory transients with prolonged plateau to a series of short [Ca 2ϩ ]i transients that return to baseline. However, pretreatment with the tyrosine kinase inhibitor genistein completely inhibited the internal Ca 2ϩ release. These results demonstrate that HIMF can stimulate intracellular Ca 2ϩ release in human pulmonary artery SMC through the PLC signaling pathway in an IP 3-and tyrosine phosphorylation-dependent manner and that G␣ q/11 proteincoupled receptor and ryanodine receptor contribute to the increase of [Ca 2ϩ ]i.
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resistin-like molecule-␣; inositol 1,4,5-trisphosphate receptor; phospholipase C; tyrosine phosphorylation; pulmonary vascular smooth muscle HYPOXIA-INDUCED MITOGENIC factor (HIMF) is a cytokine-like protein that belongs to the cysteine-rich secretory protein family resistin-like molecule (RELM)/"found in inflammatory zone" (FIZZ) (8, 12, 20) . We initially identified HIMF from an expressed sequence tag that was upregulated in a gene array of lung from a mouse chronic hypoxia-induced model of pulmonary arterial hypertension (PAH) and subsequently found it to be identical to FIZZ1 (20) .
PAH is a progressive disease of the pulmonary vessels. It is characterized by abnormal proliferation of vascular smooth muscle cells (SMC) and neointimal hyperplasia and, eventually, leads to right ventricular hypertrophy, heart failure, and, often, death (7, 9) . Our previous studies showed that HIMF expression is associated with PAH. In hypoxia-induced PAH rat and mouse models, HIMF is highly upregulated de novo in pulmonary microvascular endothelial cells and in proliferating cell nuclear antigen-positive replicating vascular SMC (20) . HIMF is also expressed in bronchial epithelial cells and alveolar type II cells (8, 20) and was increased in bleomycininduced PAH associated with pulmonary fibrosis (12) . In vitro studies showed that recombinant HIMF/FIZZ1 can stimulate the transdifferentiation of lung fibroblast cells into myofibroblasts, a cell type that actively participates in pulmonary fibrosis and vascular remodeling (11) . In vivo knockdown of HIMF expression in the chronic hypoxia model of PAH significantly reduced mean pulmonary arterial pressure, pulmonary vascular resistance, right heart hypertrophy, and vascular remodeling caused by chronic hypoxia. In addition, overexpression of HIMF in the lung caused development of pulmonary vascular remodeling and PAH (1) . In patients with scleroderma-associated pulmonary hypertension, we found that the human homolog of HIMF, RELM␤, is upregulated in the lung and induces human pulmonary vascular smooth muscle mitogenesis (2). Finally, in vivo studies from our laboratory have shown that intravenously administered recombinant HIMF is a pulmonary vasoconstrictor, dose dependently increasing pulmonary arterial pressure and pulmonary vascular resistance (20) . Despite the clear establishment of HIMF as a pulmonary vasoconstrictor and mitogen, the functional mechanism of HIMF and, in particular, its effect on pulmonary vascular smooth muscle remain unclear.
In the present study, we found that HIMF increases intracellular Ca 2ϩ concentration ([Ca 2ϩ ] i ) in human pulmonary artery SMC through activation of the inositol 1,4,5-trisphosphate (IP 3 ) receptor (IP 3 R) on the endo/sarcoplasmic reticulum. In addition, the action of HIMF on Ca 2ϩ signal was dependent on the activity of phospholipase C (PLC) and was related to protein tyrosine kinase phosphorylation and G␣ q/11 activation. MN) . The expression and puri-fication of recombinant murine HIMF tagged with FLAG peptide were described previously (16) . Because the HIMF used in this study is a FLAG-tagged fusion protein, FLAG peptide (Sigma) was used as a control. The IP 3 assay kit was purchased from Amersham (Arlington Heights, IL).
MATERIALS AND METHODS

Reagents.
Cell preparation and culture. Primary human pulmonary artery SMC (Cambrex Biosciences, Walkersville, MD) were maintained in the growth medium SGM-2 (Cambrex Biosciences) containing 5% FCS, 0.5 ng/ml human epithelial growth factor, 2 ng/ml human fibroblast growth factor, and 5 g/ml insulin under 5% CO 2 Determination of IP3. Human pulmonary artery SMC were seeded in six-well plates and treated as described above. Then the cells were exposed to HIMF for 0, 30, 60, 90, 120, or 300 s. The reaction was stopped by addition of 20% ice-cold trichloroacetic acid. The cell lysates were centrifuged at 10,000 g for 10 min at 4°C, and the supernatant containing IP3 was extracted with diethyl ether three times and neutralized with sodium bicarbonate. IP3 levels in the extract were measured with a commercially available assay kit (Amersham) according to the manufacturer's instructions. Each time point represents three separate experiments. IP3 levels are expressed as the ratio of IP3 concentration at the indicated time to IP3 concentration at baseline (C/C0).
Small interfering RNA-mediated knockdown of G␣q/11 expression. A double-stranded 23-mer small interfering RNA (siRNA) specific for G␣q/11 (sequence 5Ј-GAGCUCAAGCUGCUGCUGCUCGG-3Ј) and scrambled control siRNA were designed in our laboratory and synthesized and annealed by IDT (Coralville, IA). Transfection of siRNA was performed using the basic Nucleofactor kit for primary SMC (Amaxa Biosystems, Gaithersburg, MD) according to the manufacturer's guidelines. Briefly, human pulmonary artery SMC were trypsinized and resuspended in the basic Nucleofector solution when the cells grew to 70 -80% confluence. Then 20 pmol of siRNA were added to 20 l of cell suspension and mixed by gentle pipetting. Human pulmonary artery SMC were transiently transfected by electroporation with the Amaxa Biosystems Nucleofector II device and program FF130 and immediately transferred to wells containing prewarmed (37°C) culture medium in six-well plates. Culture medium was changed once the cells attached to the plates. Untreated cells and cells in Nucleofector solution, without siRNA and with the application of the electroporation program and with scrambled siRNA transfection, were used as negative controls. At 48 h after electroporation, the cells were lysed for immunoblot analyses to confirm the downregulation of G␣q/11 expression or used for HIMF-induced Ca 2ϩ imaging. Immunoblotting. To detect the expression of G␣q/11, human pulmonary artery SMC were lysed in Laemmli loading buffer 48 h after siRNA electroporation. Then 20 l of lysate per sample were loaded onto 4 -20% gradient polyacrylamide-sodium dodecyl sulfate gels (Bio-Rad, Hercules, CA) and transferred to nitrocellulose membranes. Membranes were blotted with rabbit anti-human G␣q/11 antibody (Santa Cruz Biotechnology, Santa Cruz, CA) and probed with horseradish peroxidase-conjugated goat anti-rabbit (Jackson ImmunoResearch Laboratories, West Grove, PA) secondary antibody. The primary antibodies were then detected by chemiluminescence (ECL, Amersham Pharmacia Biotech, Arlington Heights, IL). Mouse anti-␤-tubulin antibody (Sigma) was blotted after the membrane was stripped and used as a loading control.
Statistics and data analysis. Values are means Ϯ SE. Statistical significance was tested with Student's t-tests. P Յ 0.05 was considered significant.
RESULTS
HIMF induces intracellular Ca
2ϩ release in human pulmonary artery SMC. To determine whether HIMF can stimulate Ca 2ϩ mobilization in pulmonary SMC, we used confocal microscopy to record intracellular Ca 2ϩ changes with fluo 4 as a Ca 2ϩ indicator. In human pulmonary artery SMC preloaded with fluo 4 and maintained in Ca 2ϩ -containing buffer, extracellular application of 60 nmol/l FLAG-tagged HIMF evoked a significant increase in [Ca 2ϩ ] i , as visualized by the increase in intracellular fluorescence (Fig. 1, A and D) ; FLAG, the control peptide, had no effect (Fig. 1, B and E) . The longlasting [Ca 2ϩ ] i dynamic induced by HIMF was highly distinct from that induced by ANG II (10 Ϫ7 mol/l), which induced a rapid, transient rise in [Ca 2ϩ ] i that quickly returned to baseline, whether human pulmonary artery SMC were maintained in Ca 2ϩ -containing buffer (Fig. 1, C and F) or Ca 2ϩ -free buffer (Fig. 2, C and F (Fig. 3) . Therefore, this dose was used for the remainder of our studies.
Next we analyzed individual cells in the recording field by comparing the fluorescence intensity of an individual cell and found that ANG II initiated a rapid biphasic [Ca 2ϩ ] i transient in human pulmonary artery SMC (Fig. 4B) . In contrast, exposure of human pulmonary artery SMC to HIMF triggered an oscillatory pattern of [Ca 2ϩ ] i increase that was much more prolonged than the nonoscillatory peak and plateau response induced by ANG II (Fig. 4A) .
HIMF-induced intracellular Ca 2ϩ release via IP 3 -sensitive internal stores. The finding that [Ca 2ϩ ] i increased in human pulmonary artery SMC after exposure to HIMF, even in the absence of extracellular Ca 2ϩ , suggests that the Ca 2ϩ transient involves Ca 2ϩ release from internal stores. In vascular SMC, internal Ca 2ϩ release is initiated mainly from two functionally distinct Ca 2ϩ channels that are mediated by endo/sarcoplasmic reticulum, IP 3 R and ryanodine receptor (RyR) (15) . Therefore, we next utilized 2-APB and ryanodine (inhibitors for IP 3 R and RyR, respectively) to define which channel is responsible for the HIMF-induced Ca 2ϩ release from internal stores. Pretreatment of human pulmonary artery SMC with 50 mol/l 2-APB for 30 min at room temperature completely abolished the HIMF-induced [Ca 2ϩ ] i increase (Fig. 5A) . Blockade of RyR with an inhibitory concentration of ryanodine (100 mol/l) did not affect the initial Ca 2ϩ release from the internal stores but decreased the Ca 2ϩ levels at the plateau phase, as indicated by the reduced fluorescence (Fig. 5B) . This suggests that RyRs do not trigger the initial Ca 2ϩ activation but contribute to HIMF-induced Ca 2ϩ release in the plateau phase. These results indicate that activation of IP 3 R Ca 2ϩ channels is a prerequisite for HIMF-induced Ca 2ϩ transient in human pulmonary artery SMC, whereas RyRs are also activated by HIMF treatment and contribute to internal Ca 2ϩ release. To further confirm the involvement of IP 3 in HIMF-induced intracellular Ca 2ϩ release, IP 3 levels were measured in human pulmonary artery SMC. As shown in Fig. 5C , intracellular IP 3 increased upon HIMF stimulation, peaked at 60 s, and returned to baseline after 120 s. (Fig. 6 ). Application of U-73343, an inactive analog of U-73122, did not affect -free buffer were pretreated with the G␣ i inhibitor PTX (1 g/ml) for 1 h or the G␣ s -specific inhibitor NF-449 (10 M) for 30 min at room temperature. As shown in Fig. 7, A release; however, it affected the pattern of the Ca 2ϩ transients in response to HIMF, which showed an interval Ca 2ϩ release at reduced frequency (Fig. 8C ) compared with the oscillatory prolonged Ca 2ϩ transients in scrambled siRNA-treated cells (Fig. 8B) . Such changes in Ca 2ϩ release pattern after knockdown of G␣ q/11 suggest that G␣ q/11 protein-coupled receptor is not necessary for initiation of Ca 2ϩ release but is still significantly involved in HIMF signaling and contributes to the [Ca 2ϩ ] i of the plateau phase in human pulmonary artery SMC. Strikingly, preincubation of human pulmonary artery SMC with 10 mol/l of the tyrosine kinase inhibitor genistein completely inhibited HIMF-induced Ca 2ϩ release, whereas daidzein, an inactive analog of genistein, did not affect HIMF- induced Ca 2ϩ release (Fig. 9) . The thorough inhibition of HIMF-induced Ca 2ϩ release by genistein suggests that HIMFinduced intracellular Ca 2ϩ signaling involves activation of a tyrosine kinase and phosphorylation of tyrosine residues of certain protein(s).
HIMF-induced intracellular
DISCUSSION
To the best of our knowledge, we are the first to demonstrate that 1) HIMF induces an oscillatory increase in [ Most importantly, the involvement of tyrosine phosphorylation in HIMF signaling suggests that HIMF activation of a receptor tyrosine kinase is critical to its Ca 2ϩ signaling. Our previous work showed that Bruton's tyrosine kinase (BTK) is a binding partner for HIMF and that HIMF can bind and activate BTK in bone marrow-derived cells and initiate chemotaxis (19) , indicating that HIMF might function through intracellular receptor tyrosine phosphorylation. It is interesting to note that BTK is a critical kinase in B cell formation and differentiation and that the ability of BTK to initiate this differentiation of B cells is dependent on a prolonged oscillatory [Ca 2ϩ ] i response (17) . On the basis of our data and considering that many neurotransmitters and cytokines have multiple receptors for one ligand, we speculate that HIMF might also have multiple receptors that coordinate and contribute to the overall internal Ca 2ϩ release. HIMF has intracellular and extracellular actions, so it could also activate a membrane receptor and intracellular soluble tyrosine kinase. The present studies may provide clues to future studies aimed at identifying the membrane receptor(s) for HIMF and the FIZZ/resistin family of proteins.
HIMF may play an important role in the pathogenesis of PAH. In a chronic hypoxia model of PAH, HIMF expression is rapidly upregulated and remains elevated until day 7 (20) . Our previous study showed that recombinant HIMF activates Akt-ERK cell signaling pathways and stimulates the proliferation of pulmonary microvascular SMC. When used in vivo, HIMF constricts the pulmonary vasculature with a potency much stronger than that of serotonin, endothelin-1, and ANG II (20) , all of which can induce intracellular Ca 2ϩ increments partly through the PLC-IP 3 pathway. In contrast to the Ca 2ϩ transients induced by ANG II in human pulmonary artery SMC, which were short lived and singular, those induced by HIMF were long lasting and repetitive. This pattern of [Ca 2ϩ ] i increase might account for its potent vasoconstriction of the pulmonary vasculature.
In addition, the HIMF-induced [Ca 2ϩ ] i increase appears to be specific for pulmonary vascular SMC, inasmuch as our preliminary data show that the application of HIMF to rat primary aortic SMC did not induce [Ca 2ϩ ] i changes (data not shown), suggesting that HIMF may play a specific role in lung function or lung-related diseases. This is consistent with its localization primarily in lung. HIMF is not present in the lung vasculature under normal baseline conditions (20) but is upregulated in response to prolonged hypoxia or in response to T helper type 2 stimulation (4, 20) . Its selective expression in lung could be responsible for differences in vascular responsiveness of the pulmonary vs. systemic vascular beds following prolonged hypoxia, but its absence from the lung vasculature under normal conditions suggests that it is not a contributor to the acute physiological hypoxia pulmonary vasoconstriction response.
Using mouse lung slices, Perez and Sanderson (14) observed Ca 2ϩ oscillations induced by serotonin in smooth muscle cells of intrapulmonary arterioles, the frequency of which determines the contraction of SMC. HIMF-induced Ca 2ϩ oscillations may play a key role in the maintenance of vessel tone and contraction. De Koninck and Schulman (5) reported that Ca 2ϩ / calmodulin-dependent protein kinase II activity is sensitive to the frequency of Ca 2ϩ oscillations. The Ca 2ϩ oscillation induced by HIMF might affect intracellular cell signaling pathways by modulating some Ca 2ϩ -dependent kinase activities. In addition, abundant evidence recently has shown that intracellular Ca 2ϩ release not only triggers the excitation-contraction coupling in excitable muscle cells but also activates excitationtranscription coupling (3, 22) . The long-lasting Ca 2ϩ release by HIMF in human pulmonary artery SMC might activate the transcription of cytokines or growth factors that participate in vascular remodeling in PAH. However, further investigation of the precise molecular mechanism underlying this phenomenon is needed.
In conclusion, this study has demonstrated that HIMF stimulates Ca 2ϩ release from intracellular stores via the PLC-IP 3 pathway. This [Ca 2ϩ ] i transient is independent of extracellular Ca 2ϩ influx and is dependent on tyrosine kinase and G␣ q/11 activity. The effects of HIMF on [Ca 2ϩ ] i are consistent with HIMF action in constricting the pulmonary circulation and inducing mitogenesis of pulmonary vascular SMC.
